Skip to main content
    P

    PetMed Express Inc (PETS)

    Official site

    HEALTHCARE • PHARMACEUTICAL RETAILERS • NASDAQ

    $0.90
    -0.04 (-4.52%)

    Market Cap: $20.90M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    PetMed Express Inc (PETS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    PetMed Express reported revenue of $179.02M for the fiscal year ended Mar 31, 2026, down 21.1% from the year before. That year, net income was -$57.29M with a net margin of -32.0%, operating cash flow was -$28.39M and free cash flow was -$33.01M. The quarter ended Sep 30, 2026 had revenue of $35.77M and net income of -$6.43M.

    Revenue and Margins

    The operating margin was -32.8% in the fiscal year ended Mar 2026, the lowest of the 10 years shown. Over the 9 years to Mar 2026, revenue fell from $249.18M, a compound annual decline of 3.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$179.02M-21.1%28.1%-32.8%-32.0%
    Mar 2025$226.97M-17.2%30.5%-0.7%-2.8%
    Mar 2024$274.10M+10.7%30.9%-3.0%-2.7%
    Mar 2023$247.57M-9.1%30.9%2.4%2.1%
    Mar 2022$272.28M-10.3%28.3%8.9%6.9%
    Mar 2021$303.58M+6.8%27.8%10.1%7.9%
    Mar 2020$284.13M+0.2%28.6%10.9%9.1%
    Mar 2019$283.42M+3.5%33.6%16.3%13.3%
    Mar 2018$273.80M+9.9%35.7%19.0%13.6%
    Mar 2017$249.18MN/A31.8%15.0%9.6%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$179.02M$226.97M$274.10M$247.57M$272.28M$303.58M$284.13M$283.42M$273.80M$249.18M
    Cost of revenue$128.81M$157.84M$189.33M$171.07M$195.34M$219.27M$202.88M$188.10M$175.99M$169.86M
    Gross profit$50.22M$69.14M$84.77M$76.50M$76.94M$84.32M$81.25M$95.31M$97.81M$79.31M
    Operating income-$58.67M-$1.53M-$8.16M$6.05M$24.29M$30.53M$30.98M$46.17M$52.14M$37.48M
    Net income-$57.29M-$6.27M-$7.46M$5.14M$18.72M$23.92M$25.85M$37.74M$37.28M$23.82M
    EBITDA-$48.48M$6.27M$272.00K$10.54M$28.05M$34.27M$34.40M$49.48M$55.26M$39.15M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$35.77M$41.02M$42.82M$40.66M$44.36M$51.18M$50.76M$51.96M$58.04M$66.21M$59.53M$65.32M
    Gross profit$9.80M$11.33M$13.94M$9.46M$12.41M$14.40M$15.20M$16.13M$18.77M$19.04M$24.30M$17.88M
    Operating income-$6.42M-$6.23M-$5.69M-$10.47M-$8.38M-$34.13M-$6.02M-$450.00K$554.00K$4.39M-$3.83M-$3.07M
    Net income-$6.43M-$6.14M-$4.06M-$10.55M-$8.52M-$34.15M-$11.64M-$707.00K$2.33M$3.75M-$5.02M-$2.03M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded short-term debt of $493.00K by $20.92M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$81.19M$148.70M$169.88M$167.48M$179.70M$187.50M$155.32M$154.43M$134.84M$112.81M
    Current assets$43.56M$78.87M$93.65M$130.43M$151.00M$161.19M$129.02M$126.43M$105.23M$81.78M
    Cash and equivalents$21.41M$54.72M$55.30M$104.09M$111.08M$118.72M$103.76M$100.53M$77.94M$58.73M
    Total liabilities$52.25M$63.57M$73.15M$57.51M$56.25M$46.22M$25.31M$19.75M$19.11M$19.44M
    Short-term debt$493.00KN/A$459.00KN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$28.94M$85.13M$96.73M$109.97M$123.45M$141.28M$130.01M$134.68M$115.73M$93.37M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$59.40M$63.76M$81.19M$87.97M$100.30M$109.84M$148.70M$144.79M$146.03M$152.71M$175.09M$173.35M
    Total liabilities$42.54M$40.77M$52.25M$55.20M$57.24M$58.29M$63.57M$48.61M$49.60M$59.18M$78.36M$73.29M
    Cash and equivalents$11.42M$13.08M$21.41M$26.91M$36.10M$41.13M$54.72M$50.10M$52.05M$45.99M$55.30M$49.44M
    Shareholder equity$16.86M$22.99M$28.94M$32.77M$43.06M$51.55M$85.13M$96.18M$96.43M$93.53M$96.73M$100.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$28.39M$4.72M$4.32M$27.80M$18.50M$40.08M$38.84M$45.14M$37.38M$47.20M
    Capital expenditures$4.62M$5.11M$4.51M$5.26M$1.75M$2.43M$2.31M$620.00K$703.00K$10.60M
    Free cash flow-$33.01M-$395.00K-$194.00K$22.54M$16.75M$37.64M$36.53M$44.52M$36.68M$36.60M
    Dividends paid$21.00K$181.00K$12.44M$24.54M$24.38M$22.69M$21.80M$21.93M$17.47M$15.51M
    Share repurchasesN/AN/AN/AN/AN/AN/A$11.50M$0$0N/A
    Investing cash flow-$4.62M-$5.11M-$40.67M-$10.26M-$1.75M-$2.43M-$2.31M-$620.00K-$703.00K-$10.60M
    Financing cash flow-$299.00K-$181.00K-$12.44M-$24.54M-$24.38M-$22.69M-$33.30M-$21.93M-$17.47M-$15.51M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.06M-$7.69M-$4.74M-$9.21M-$2.17M-$12.27M$7.01M-$1.17M$7.39M-$8.52M$7.13M-$2.59M
    Capital expenditures$586.00K$641.00K$720.00K$21.00K$2.62M$1.29M$2.39M$777.00K$1.26M$683.00K$1.25M$1.12M
    Free cash flow-$1.64M-$8.33M-$5.46M-$9.23M-$4.80M-$13.56M$4.62M-$1.94M$6.12M-$9.20M$5.87M-$3.72M
    Last 12 quarters

    Frequently Asked Questions About PETS

    What is PetMed Express' annual revenue?

    PetMed Express reported revenue of $179.02M for the fiscal year ended Mar 31, 2026.

    How fast is PetMed Express' revenue growing?

    Revenue was down 21.1% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -10.2%.

    Is PetMed Express profitable?

    No. PetMed Express reported net income of -$57.29M for the fiscal year ended Mar 31, 2026, with a net margin of -32.0%.

    How much free cash flow does PETS generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$28.39M minus capital expenditures of $4.62M produced free cash flow of -$33.01M.

    How much debt does PetMed Express have?

    The balance sheet dated Mar 31, 2026 reported short-term debt of $493.00K and cash and equivalents of $21.41M.